AIN457 150 mg
CAIN457A2304E1
Phase 3 small_molecule completed
Quick answer
AIN457 150 mg for Moderate to Severe Chronic Plaque-Type Psoriasis is a Phase 3 program (small_molecule) at Novartis Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Pharmaceuticals
- Indication
- Moderate to Severe Chronic Plaque-Type Psoriasis
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed